Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7EK | ISIN: JP3431300007 | Ticker-Symbol: JSS
Frankfurt
28.03.24
08:22 Uhr
9,700 Euro
+0,150
+1,57 %
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
SOSEI GROUP CORPORATION Chart 1 Jahr
5-Tage-Chart
SOSEI GROUP CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
9,70010,20028.03.

Aktuelle News zur SOSEI GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSosei Group Corporation: Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma43Tokyo, Japan and Cambridge, UK, 27 March 2024 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the...
► Artikel lesen
21.03.Sosei Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease387LONDON (dpa-AFX) - Sosei Group Corp. said it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in...
► Artikel lesen
21.03.Sosei Group Corporation: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease65HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 - Sosei Group Corporation ("Sosei...
► Artikel lesen
21.03.Sosei Group Corporation: Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease59GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
► Artikel lesen
11.03.Boehringer, Sosei Heptares team up in schizophrenia drug deal9
11.03.Boehringer Ingelheim Places €25M Bet on Sosei's Novel Approach to Schizophrenia9
11.03.Boehringer, Sosei Heptares Partner on Schizophrenia Precision Treatment3
11.03.Boehringer boosts schizophrenia strategy with €25M upfront for option on Sosei's GPR52 agonists3
11.03.Boehringer licenses Sosei schizophrenia drugs in €755m deal2
11.03.Boehringer and Sosei Heptares partner on schizophrenia treatment1
11.03.Sosei Group Corporation: Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia124Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive...
► Artikel lesen
06.03.Sosei Heptares Earns $2.5M Formosa Milestone1
06.03.Sosei Group Corporation: Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals637Tokyo, Japan and Cambridge, UK, 6 March 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has received approval...
► Artikel lesen
16.02.Sosei ushers in new era with Nxera Pharma name change2
16.02.Sosei Group Corporation: Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office151Tokyo, Japan and Cambridge, UK, 16 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
► Artikel lesen
13.02.Sosei Group reports FY results1
13.02.Sosei Heptares reports mixed annual results, plans for growth1
13.02.Sosei Group Corporation: Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023136Tokyo, Japan and Cambridge, UK, 13 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated...
► Artikel lesen
22.01.Sosei Group Corporation: Sosei Heptares Webinar Presentation for FY2023 Financial Results2
05.01.Sosei Group Corporation: Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer534Tokyo, Japan and Cambridge, UK, 5 January 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer...
► Artikel lesen
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1